Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 20/20 | 1.00 |
| ▸ | LGALS1 | P09382 | 10/20 | 1.00 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17432841 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| SCHEMBL19678781 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| SCHEMBL19630815 | 0.91 | LGALS3 (0.87) | LGALS3LGALS1 | |
| SCHEMBL19630741 | 0.91 | LGALS3 (0.87) | LGALS3LGALS1 | |
| SCHEMBL19630770 | 0.91 | LGALS3 (0.87) | LGALS3LGALS1 | |
| SCHEMBL19630664 | 0.90 | LGALS3 (0.82) | LGALS3LGALS1LGALS8 | |
| SCHEMBL19630663 | 0.90 | LGALS3 (0.82) | LGALS3LGALS1LGALS8 | |
| SCHEMBL19630717 | 0.90 | LGALS3 (0.82) | LGALS3LGALS1 | |
| SCHEMBL19630703 | 0.90 | LGALS3 (0.82) | LGALS3LGALS1LGALS8 | |
| SCHEMBL19630660 | 0.90 | LGALS3 (0.82) | LGALS3LGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800804-B2 | Hybrid galactoside inhibitor of galectins | GALECTO BIOTECH AB | 2020-10-13 | — | — | US | disclosed |
| US-10253059-B2 | Hybrid galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2019-04-09 | — | — | US | disclosed |
| US-20170349622-A1 | NOVEL HYBRID GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253059-B2 | Hybrid galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885LGALS8 8/4885 |
| US-10800804-B2 | Hybrid galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS3BP | LGALS3 2/4885LGALS1 1/4885LGALS8 8/4885 |
| US-20170349622-A1 | NOVEL HYBRID GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885LGALS8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.